GNS Healthcare and Swedish Cancer Institute Launch Machine Learning Collaboration
September 14, 2017
GNS Healthcare (GNS) and the Swedish Cancer Institute (SCI) are pleased to announce a machine learning collaboration to strengthen, accelerate, and potentially expand the delivery of precision medicine in breast cancer care.
GNS will employ its breakthrough causal machine learning and simulation platform REFS™ (Reverse Engineering and Forward Simulation) to build computer models and ultimately a software interface tool that will link clinical and molecular data to treatment and outcomes across SCI’s patient population. The collaboration will use aggregated patient data from SCI’s Breast Cancer Research Registry, and Personalized Medicine Research Program (PMRP), to build these computer models.
REFS-generated models can support clinical decision-making through a better understanding of treatment success based on individualized genetic backgrounds. These models can be used to simulate potential treatment interventions and their effect on disease outcomes. The results of these analyses can then be interpreted through GNS’s software interface to support optimal delivery of treatments to individual patients.
“Few oncologists today have the complete training or time necessary to decipher complex results of a tumor’s biologic fingerprint. GNS’ REFS-generated models will streamline this process and enhance our PMRP’s work to support providers and their patients with treatment recommendations,” said Thomas Brown, MD, Executive Director of the Swedish Cancer Institute. “This unique collaboration is intended to facilitate the practice of personalized, i.e. precision, medicine at the SCI, increasing access of this important resource to our patients, while allowing our doctors to remain patient-focused.”
Dr. Henry Kaplan, Head of Breast Medical Oncology, and Principal Investigator of the Breast Cancer Research Registry, emphasized that “this project has the potential to optimize use of genomic information in the care of our breast cancer patients, to include through our SCI Molecular Tumor Board.”
“SCI is a clear trailblazer in precision medicine, and we are honored to be collaborating on this effort that not only brings great value to SCI patients and providers, but also demonstrates how to leverage technology to scale the delivery of precision medicine,” said Iya Khalil, PhD, Co-Founder and Chief Commercial Officer of GNS. “This collaboration is the first of its kind in establishing an enhanced precision medicine capability and holistic disease understanding.”
By automating the process of connecting cancer patients with their most effective treatment, the GNS-SCI collaboration demonstrates a framework for scaling precision medicine initiatives. These efforts set the stage for a more expansive program capable of making discoveries that can deliver value for a range of healthcare stakeholders in the future.